Menu

Search

  |   Business

Menu

  |   Business

Search

Faraday Pharmaceuticals Announces First-In-Human Trial of FDY-5301

SEATTLE - Faraday Pharmaceuticals, a biopharmaceutical company focused on the development of elemental reducing agents for critical care medicine, today announced the start of a Phase 1 clinical trial evaluating its lead compound FDY-5301.

The randomized, double blind, placebo-controlled trial is designed to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of single, escalating, intravenous doses of FDY-5301 versus placebo in healthy volunteers. FDY-5301 contains elemental iodine in its reduced form – iodide – formulated for intravenous administration.

Preclinical data have demonstrated the ability of FDY-5301 to diminish reperfusion injury in both cardiac and skeletal muscle in a range of different animal models and in multiple species. The Phase 1 trial is being conducted in Australia and is targeted to enroll approximately 40 subjects.

"It's gratifying to begin this first-in-human study following the promising preclinical findings to date, and less than six months after our initial 'GLP' toxicity studies were initiated. Our elemental reducing agents have demonstrated compelling activity in a number of animal studies, including models of cardiac reperfusion, radiation injury and organ transplantation," said Stephen A. Hill, M.D., Chief Executive Officer of Faraday. "We are working hard on our Phase 2 preparations in hope of providing new options to patients as expeditiously as possible."

Faraday Pharmaceuticals is a biopharmaceutical company focused on the research and development of elemental reducing agents (ERAs). These therapeutic agents have potential applications for treatment of critical care illnesses. The company is headquartered in Seattle. 

  • ET PRO
  • Market Data

Market-moving news and views, 24 hours a day >

August 23 00:30 UTC Released

JPNikkei Mfg PMI

Actual

52.8 bln $

Forecast

Previous

52.1 bln $

August 22 14:00 UTC Released

USRich Fed Mfg Shipments*

Actual

8 %

Forecast

Previous

13 %

August 23 07:00 UTC 4343m

TRConsumer Confidence*

Actual

Forecast

Previous

71.3 %

August 23 07:00 UTC 4343m

FRMarkit Mfg Flash PMI

Actual

Forecast

54.5 bln $

Previous

54.9 bln $

August 23 07:00 UTC 4343m

FRMarkit Comp Flash PMI

Actual

Forecast

55.5 %

Previous

55.6 %

August 23 07:00 UTC 4343m

FRMarkit Serv Flash PMI

Actual

Forecast

55.8 %

Previous

56.0 %

August 23 07:30 UTC 7373m

DEMarkit Comp Flash PMI

Actual

Forecast

54.7

Previous

54.7

August 23 07:30 UTC 7373m

DEMarkit Service Flash PMI

Actual

Forecast

53.3

Previous

53.1

August 23 07:30 UTC 7373m

DEMarkit Mfg Flash PMI

Actual

Forecast

57.7

Previous

58.1

August 23 08:00 UTC 103103m

EZMarkit Mfg Flash PMI

Actual

Forecast

56.3 bln EUR

Previous

56.6 bln EUR

Close

Welcome to EconoTimes

Sign up for daily updates for the most important
stories unfolding in the global economy.